Changes of central macular thickness post intravitreal ranibizumab and its associated factors among diabetic macular oedema patients
Background: Intravitreal Ranibizumab (IVR) which is an anti-vascular endothelial growth factor (anti-VEGF) has become the preferred treatment option to improve the vision of diabetic macular oedema (DMO) patients. IVR acts by inhibits VEGF-A from binding to its receptors, leading to decreased in vas...
Saved in:
Main Author: | |
---|---|
Format: | Thesis |
Language: | English |
Published: |
2020
|
Subjects: | |
Online Access: | http://eprints.usm.my/51000/1/Nursyafiqah%20Md%20Tahir-24%20pages.pdf |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Be the first to leave a comment!